ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Alnylam Pharmaceuticals
Summary
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Eligibility
- Age range
- Not specified
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers * Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis Exclusion Criteria: * Current enrollment in a clinical trial for any investigational agent
Locations (40)
- Clinical Trial SiteLa Jolla, California
- Clinical Trial SiteLos Angeles, California
- Clinical Trial SiteJacksonville, Florida
- Clinical Trial SiteIowa City, Iowa
- Clinical Trial SiteKansas City, Kansas
- Clinical Trial SiteBaltimore, Maryland